Lodi Mariachiara, Boccuto Luigi, Carai Andrea, Cacchione Antonella, Miele Evelina, Colafati Giovanna Stefania, Diomedi Camassei Francesca, De Palma Luca, De Benedictis Alessandro, Ferretti Elisabetta, Catanzaro Giuseppina, Pò Agnese, De Luca Alessandro, Rinelli Martina, Lepri Francesca Romana, Agolini Emanuele, Tartaglia Marco, Locatelli Franco, Mastronuzzi Angela
Department of Paediatric Haematology/Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
School of Nursing, College of Behavioral, Social and Health Sciences, Clemson University, Clemson, SC 29634, USA.
Diagnostics (Basel). 2020 Aug 12;10(8):582. doi: 10.3390/diagnostics10080582.
Noonan syndrome (NS) is a congenital autosomic dominant condition characterized by a variable spectrum from a clinical and genetical point of view. Germline mutations in more than ten genes involved in RAS-MAPK signal pathway have been demonstrated to cause the disease. An higher risk for leukemia and solid malignancies, including brain tumors, is related to NS. A review of the published literature concerning low grade gliomas (LGGs) in NS is presented. We described also a 13-year-old girl with NS associated with a recurrent mutation in , who developed three different types of brain tumors, i.e., an optic pathway glioma, a glioneuronal neoplasm of the left temporal lobe and a cerebellar pilocytic astrocytoma. Molecular characterization of the glioneuronal tumor allowed to detect high levels of phosphorylated MTOR (pMTOR); therefore, a therapeutic approach based on an mTOR inhibitor (everolimus) was elected. The treatment was well tolerated and proved to be effective, leading to a stabilization of the tumor, which was surgical removed. The positive outcome of the present case suggests considering this approach for patients with RASopathies and brain tumors with hyperactivated MTOR signaling.
努南综合征(NS)是一种常染色体显性先天性疾病,从临床和遗传学角度来看具有多种表现形式。已证实,参与RAS-MAPK信号通路的十多个基因中的种系突变可导致该疾病。NS患者患白血病和实体恶性肿瘤(包括脑肿瘤)的风险较高。本文对已发表的有关NS患者低级别胶质瘤(LGG)的文献进行了综述。我们还描述了一名13岁患有NS的女孩,其 存在复发性突变,她患了三种不同类型的脑肿瘤,即视神经通路胶质瘤、左侧颞叶神经胶质神经元肿瘤和小脑毛细胞型星形细胞瘤。对神经胶质神经元肿瘤的分子特征分析发现磷酸化MTOR(pMTOR)水平较高;因此,选择了基于mTOR抑制剂(依维莫司)的治疗方法。该治疗耐受性良好且被证明有效,使肿瘤稳定,随后进行了手术切除。本病例的积极结果表明,对于患有RAS病且MTOR信号过度激活的脑肿瘤患者可考虑采用这种治疗方法。